drugset / Trial / NCT02674399

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

NCT02674399

Phase 2 Completed 28 enrolled Nature Cell Co. Ltd. KCRN Research, LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a double-blind, randomized, controlled study with two arms to evaluate JointStem as a treatment for subjects with osteoarthritis. Following a 2-week screening period, approximately 30 subjects will be randomly assigned into one of the following two arms in a 2:1 ratio (2 JointStem : 1 positive control). After each subject completes 6-month visit (Visit 6) and the data management team confirms all data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.Only subjects who are assigned will be requested to visit the study center for 9-month and 12-month follow-up visits (Visits 7 and 8). To see long-term effects of JointStem, all subjects who complete Visit 6 will be requested to visit the study center at 24-month after the injection.

Timeline

Start
2016-02-16
Primary completion
2018-03-12
Completion
2018-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous adipose-derived mesenchymal stem cells Cell therapy Other
Comparator Hylan G-F 20 Other / unclassified Other

Indications